Grappling with allegations of improper sales practices, Alexion Pharmaceuticals has announced a failure of a Phase II/III trial for expanded use of Soliris.
Ophthotech is cutting up to 135 jobs following the failure of its two Phase III clinical trials combining the company’s Fovista and Genentech’s Lucentis to treat wet AMD.
Intouch Solutions has announced the promotion of six employees in its Chicago office.
Global pharmaceutical company AstraZeneca is delivering unwanted Christmas presents in the form of pink slips to 700 employees across the United States, with about 150 being terminated in Delaware.
Valeant appointed Paul S. Herendeen as executive VP of Finance and chief financial officer. Also, Louis W. Yu, Ph.D. joined Valeant as chief quality officer, Global Quality.
Julian Adams, Ph.D., was appointed chairman of the board of directors at Gamida Cell Ltd.
David A. Spiegel, M.D., Ph.D., is now CEO of Kleo Pharmaceuticals Inc.
Kenneth I. Moch has been appointed president and CEO of Cognition Therapeutics Inc.
Debra K. Bowes has joined MaxCyte Inc. as executive VP, Business and Strategic Development.